← Back

PathMaker Neurosystems is Named as a Top 6 Neuroscience Startup at The Brain Forum conference

Boston, Mass., USA, and Paris, France (June 25, 2016) — PathMaker Neurosystems Inc. (“PathMaker”), a clinical-stage neurotechnology company developing non-invasive neurotherapy systems for the treatment of patients with neuromotor disorders, has been named as a Top 6 Neuroscience Startup at the international conference of The Brain Forum in Lausanne, Switzerland.

Presentation to the Forum audience by PathMaker’s CEO, Dr. Nader Yaghoubi
Presentation to the Forum audience by PathMaker’s CEO, Dr. Nader Yaghoubi

The Brain Forum is dedicated to helping fulfil the potential of brain science to benefit humanity, through the treatment of neurological disorders and the enhancement of everyday life. The annual forum held this year in May brought together more than 1,400 researchers, engineers, healthcare professionals, entrepreneurs, industrialists, investors, funding agencies, and policy makers from 31 countries.

PathMaker was selected as a Top 6 European Neuroscience Startup. Dr. Nader Yaghoubi shown with CEO of The Brain Forum, Dr. Jamil El-Imad
PathMaker was selected as a Top 6 European Neuroscience Startup. Dr. Nader Yaghoubi shown with CEO of The Brain Forum, Dr. Jamil El-Imad

PathMaker was selected as one of just six finalists to be named as a Top European Neuroscience Startup in the Innovation Award competition.  “PathMaker was delighted and honored to have been selected this year as a Top Neuroscience Startup at The Brain Forum conference,” said Nader Yaghoubi, M.D., Ph.D., President and Chief Executive Officer of PathMaker. “The organizers have brought together some of the world’s leading neuroscientists for a premiere conference that uniquely integrates academia, industry and early-stage companies focused on neuroscience.”

Six early-stage companies were selected as Top 6 European Neuroscience companies
Six early-stage companies were selected as Top 6 European Neuroscience companies

PathMaker is developing breakthrough non-invasive systems that treat patients suffering from neuromotor conditions brought on by stroke, cerebral palsy, multiple sclerosis, Parkinson’s disease, traumatic brain injury and spinal cord injury. There are more than 48 million affected patients in the U.S., Europe, and China alone with these conditions. PathMaker’s first product, MyoRegulator™, provides a breakthrough non-invasive treatment for muscle spasticity and is now in IRB-approved human clinical trials. The company’s second product, MyoAmplifier™, provides an advanced non-invasive platform that treats paralysis and muscle weakness.

Conference organizers have posted the six minute presentation and Q&A made to the Forum by Nader Yaghoubi, M.D., Ph.D., President and Chief Executive Officer of PathMaker, which can be viewed here.

About PathMaker Neurosystems Inc.

PathMaker Neurosystems Inc. is a clinical-stage neurotechnology company developing non-invasive neurotherapy systems based on PathMaker Coordinated Multi-Site Neurostimulation™. With offices in Boston (US) and Paris (France), PathMaker is moving forward a trans-Atlantic strategy to rapidly bring to market entirely novel, breakthrough approaches to non-invasively treating neuromotor disorders. More than 48 million patients in the US, Europe and China suffer disabilities due to stroke, cerebral palsy, multiple sclerosis, spinal cord injury, traumatic brain injury, Parkinson’s disease and other neurological disorders. At PathMaker, we are opening up a new era of non-invasive neurotherapy for patients suffering from chronic neuromotor conditions. Visit the company website at www.pmneuro.com.

Press Contact: Don Goncalves, Tiziani Whitmyre, 781.793.9380, dgoncalves@tizinc.com